Ad-116a

Phase 1

AAddpharma Inc.

Ad-116a is one of 27 therapeutic programs targeting Benign Prostatic Hyperplasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Benign Prostatic HyperplasiaNot yet recruiting

Benign Prostatic HyperplasiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

36 competitors in Benign Prostatic Hyperplasia

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

25 2

Cialis

Eli Lilly

Approved

19 3

Rapaflo

AbbVie

Approved

10 4

Myrbetriq

Astellas

Approved

2 5

Vesicare

Astellas

Approved

1 6

Avodart

Akero Therapeutics

Approved

8 7

Uroxatral

AAdvanz Pharma

Approved

6 8

Minipress

Taxol

Propecia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Benign Prostatic Hyperplasia

NCT07722871

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia2 trials

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07722871·44 enrolled

An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07715305·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ad-116a. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ad-116a. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Addpharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAddpharma Inc.

Ad-116a

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Benign Prostatic Hyperplasia2 trials

References

Drug Info

Quick Facts

Related News